<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450176</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-04-11</org_study_id>
    <secondary_id>3776-001</secondary_id>
    <nct_id>NCT01450176</nct_id>
  </id_info>
  <brief_title>Comparing Patient Satisfaction With Pataday or Bepreve</brief_title>
  <official_title>Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McCabe Vision Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McCabe Vision Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine
      hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution
      1.5%) two times a day (BID).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5 week randomized study with 15 subjects using Pataday qd for 2 weeks, and the other 15
      subjects using Bepreve BID for 2 weeks. Following a one-week washout period, the two groups
      are given the opposite test article (TA) for 2 weeks. Subjects to complete daily diary
      regarding effects of drug and are seen in clinic for 3 exams.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of ocular itching</measure>
    <time_frame>5 weeks</time_frame>
    <description>All day relief of ocular itching throughout the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>5 weeks</time_frame>
    <description>Patient satisfaction, preference, and comfort with treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Eye Allergies</condition>
  <arm_group>
    <arm_group_label>Pataday once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bepreve twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine hydrochloride 0.2%</intervention_name>
    <description>1 drop in each eye once daily for 2 weeks</description>
    <arm_group_label>Pataday once daily</arm_group_label>
    <other_name>Pataday</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepotastine besilate ophthalmic solution 1.5%</intervention_name>
    <description>1 drop in each eye twice daily for 2 weeks</description>
    <arm_group_label>Bepreve twice daily</arm_group_label>
    <other_name>Bepreve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male or female subjects of any racial/ethnic group.

          -  Be at least 18 years of age or older.

          -  Have a diagnosis of allergic conjunctivitis with active symptoms, with no concurrent
             ocular allergy associated conditions and no plans to have ocular surgery during study
             period.

          -  Willing and able to return for all required visits and follow instructions from
             investigator and staff.

          -  Able to self-administer test article (TA) or have a caregiver available to instill all
             doses of TA.

          -  If a woman, capable of becoming pregnant, agrees to have pregnancy testing performed
             at screening (must be negative) and agrees to use a medically acceptable form of birth
             control (intrauterine device, birth control pill, patch or subcutaneous implant,
             condoms, diaphragm, and abstinence) throughout the study duration and for at least one
             week prior to and one week after completion of the study. Women considered capable of
             becoming pregnant include all females who have experienced menarche and who have not
             experienced menopause (as defined by amenorrhea for greater than 12 consecutive
             months) or have not undergone successful surgical sterilization (hysterectomy,
             bilateral tubal ligation, or bilateral oophorectomy).

          -  Sign and date the informed consent form approved by an Institutional Review Board
             (IRB)/Independent Ethics Committee (IEC).

          -  Be willing/able to return for all required study visits, to follow instructions from
             the study investigator and his/her staff, and to complete and return the Screening and
             Subject Diaries.

        Exclusion Criteria:

          -  Have known hypersensitivity to BEPREVE or PATADAY or any of their components.

          -  Are actively taking steroids or antihistamines during the study or within 7 days prior
             to enrolling in the study.

          -  Are pregnant, planning to become pregnant, or nursing/lactating.

          -  Have a known history of alcohol or drug abuse.

          -  Participated in a study of an investigational drug or device within the past 30 days
             prior to enrolling in the study.

          -  Have a presence of an active ocular infection (bacterial, viral or fungal), positive
             history of an ocular herpetic infection, or preauricular lymphadenopathy at any visit.

          -  Have any significant illness {eg: any autoimmune disease, or severe cardiovascular
             disease (including arrhythmias)}that the Investigator feels could be expected to
             interfere with the subject's safety or study parameters and/or put the subject at anyh
             unnecessary risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>McCabe Vision Center</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eye</keyword>
  <keyword>itching</keyword>
  <keyword>allergies</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

